Displaying drugs 14851 - 14875 of 15210 in total
Xibornol
Experimental
Guanoclor
Experimental
Motexafin lutetium
Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. Motexafin lutetium is a pentadentate aromatic metallotexaphyrin with photosensitizing properties.
Investigational
Talviraline
Talviraline has been used in trials studying the treatment of HIV Infections.
Investigational
4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
Experimental
Dexetimide
A muscarinic antagonist that has been used to treat neuroleptic-induced parkinsonism. Benzetimide is the (-)-enantimorph of dexetimide.
Withdrawn
Mephenoxalone
Experimental
A-98881
Experimental
BMS-564929
BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.
Experimental
CCT-018159
Experimental
SO-101
SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected for its use in insomnia. Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day.
Investigational
Matched Description: … Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages …
Reproxalap
Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome. NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.
Investigational
Matched Description: … Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and …
EHT899
EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.
Investigational
Matched Description: … enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and …
RUS 3108
RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories.
The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers.
Investigational
Matched Description: … the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and …
OSI-7904L
OSI-7904L is a liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA). Current treatments also inhibit thymidylate synthase but the innovative lipid coating of OSI-7904L allows for more enduring results with administration of the TS inhibitor.
Investigational
Matched Description: … liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced gastric and …
2,5-Dimethoxy-4-(n)-propylthiophenethylamine
Experimental
Illicit
4-Bromo-2,5-dimethoxyphenethylamine
Experimental
Illicit
Displaying drugs 14851 - 14875 of 15210 in total